Topic: autism spectrum disorders
EIP Pharma is enrolling a phase 2b trial of neflamapimod, which targets synaptic dysfunction.
Instead of seeking the underlying cause of a group of symptoms, scientists started with a mutation and then tracked down people who have it.
Roche has been awarded breakthrough status for a drug that has shown some signs of activity in autism spectrum disorders, according to reports.
A new target for the treatment of MeCP2 duplication syndrome could be useful in treating autism and other neurological conditions.
Researchers led by McGill University are investigating whether the diabetes drug metformin might effectively treat fragile X syndrome, a cause of autism.